Nasdaq:IRMD
IRADIMED CORP
A growing developer of advanced medical diagnostics and data analytics platforms serving global healthcare and life sciences markets.
Key Metrics
Investment Thesis
Bull Case
Investors should consider IRMD as a high-growth small-cap opportunity with expanding revenue and positive operating cash flow generation. The consistent year-over-year increase in both revenue and net income suggests effective execution of its product roadmap and market penetration strategy. With total assets growing to nearly $100M and manageable current liabilities, the balance sheet supports continued R&D investment without immediate dilution concerns.
Bear Case
The substantial retained earnings deficit of $56.8M relative to recent profits indicates a history of significant cash consumption that may continue if growth slows. Current assets are predominantly tied up in accounts receivable, creating liquidity pressure if clients delay payments or if the economic environment tightens credit conditions. Limited operating leverage and heavy reliance on external financing flows (-$14.3M from financing) could constrain capital flexibility during downturns.
About IRADIMED CORP
IRADiMED Corp. specializes in advanced medical technologies providing diagnostic solutions to healthcare providers and life sciences companies globally. The company leverages proprietary software and hardware to deliver high-quality imaging and analysis tools that support clinical decision-making. Revenue growth over the last three years reflects increasing adoption of their platform across key therapeutic areas.
Analysis
Management Discussion
Management successfully drove revenue from $53.3M in 2022 to $73.2M in 2024, demonstrating consistent top-line expansion and improved gross margins. Operating cash flow of $25.6M provides strong liquidity for reinvestment, evidenced by capital expenditures totaling $8.0M and significant share buybacks or financing activities reducing cash reserves slightly year-over-year. While net income grew steadily, the company maintains a substantial retained earnings deficit of $56.8M, indicating historical burn or aggressive early-stage growth strategies.
Industry Overview
The medical diagnostics industry is characterized by rapid technological innovation driven by artificial intelligence and big data analytics, creating opportunities for specialized players like IRADiMED. Market participants face intense competition from large established incumbents while navigating complex global regulatory landscapes regarding device safety and efficacy. Consolidation trends favor companies with robust IP portfolios that can command premium pricing through differentiated clinical outcomes.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $53.3M | $65.6M | $73.2M |
| Cost of Revenue | $12.0M | $15.4M | $16.9M |
| Gross Profit | $41.3M | $50.2M | $56.3M |
| Operating Expenses | $25.7M | $30.1M | $34.4M |
| Operating Income | $15.6M | $20.0M | $22.0M |
| R&D | $2.3M | $2.9M | $2.8M |
| G&A | $10.7M | $15.1M | $15.9M |
| Marketing | $12.7M | $12.1M | $15.6M |
| Stock-Based Comp | $1.4M | $2.2M | $2.5M |
| D&A | $670.7K | $765.2K | $817.7K |
| Depreciation | — | $648.1K | $585.5K |
| Amortization | $101.1K | $117.0K | $232.1K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $553.1K | $1.7M | $2.3M |
| Interest Income | $581.9K | $1.9M | $2.2M |
| Pre-Tax Income | $16.2M | $21.7M | $24.3M |
| Income Tax | $3.4M | $4.5M | $5.0M |
| Continuing Ops | $12.8M | $17.2M | $19.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $12.8M | $17.2M | $19.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $12.8M | $17.2M | $19.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $77.5M | $76.0M | $75.2M |
| Cash & Equivalents | $58.0M | $49.8M | $52.2M |
| Accounts Receivable | $13.3M | $12.2M | $10.6M |
| Inventory | $5.4M | $12.8M | $10.4M |
| Prepaid Expenses | $631.0K | $1.2M | $2.0M |
| Other Current Assets | $254.1K | $0 | $0 |
| Long-Term Assets | $8.0M | $16.2M | $23.1M |
| PP&E (Net) | $2.4M | $9.3M | $16.8M |
| Operating Leases | $2.2M | $2.0M | $154.7K |
| Other LT Assets | $3.4M | $4.8M | $6.1M |
| Total Assets | $85.5M | $92.2M | $98.3M |
| Current Liabilities | $8.6M | $16.3M | $8.5M |
| Accounts Payable | $1.8M | $1.9M | $1.9M |
| Current Leases | $293.5K | $428.0K | $153.3K |
| Deferred Revenue | $3.4M | $2.6M | $2.3M |
| Taxes Payable | — | $250.0K | — |
| Other Current Liab | $3.1M | $3.2M | $4.2M |
| Long-Term Liabilities | $3.3M | $4.4M | $3.0M |
| LT Operating Leases | $1.9M | $1.6M | $1.4K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $11.8M | $20.7M | $11.5M |
| Shareholders' Equity | $73.7M | $71.4M | $86.8M |
| Paid-In Capital | $26.4M | $28.2M | $30.0M |
| Retained Earnings | $47.3M | $43.3M | $56.8M |
| Total L&E | $85.5M | $92.2M | $98.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $12.8M | $17.2M | $19.2M |
| Non-Cash Adjustments | $-17.0M | $-12.4M | $11.0M |
| Working Capital Changes | $14.2M | $8.7M | $-4.7M |
| Cash from Operations | $10.0M | $13.5M | $25.6M |
| Capital Expenditures | $823.0K | $7.4M | $8.0M |
| Cash from Investing | $-1.4M | $-8.0M | $-8.8M |
| Dividends Paid | $12.6M | $13.2M | $13.7M |
| Cash from Financing | $-12.7M | $-13.7M | $-14.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-4.0M | $-8.2M | $2.5M |
| Beginning Cash | $62.0M | $58.0M | $49.8M |
| Ending Cash | $58.0M | $49.8M | $52.2M |
Frequently Asked Questions
How does IRADIMED CORP make money?
The company generates revenue primarily through the sale of proprietary diagnostic imaging systems, software licenses for clinical data analysis, and ongoing maintenance or service contracts. Additional streams include strategic partnerships with research institutions and potential licensing of intellectual property to third-party pharmaceutical firms.
What are the main risks for IRMD?
The company faces significant concentration risk given that current assets are heavily weighted toward receivables and limited diversification across end-users. Regulatory changes in medical device approval processes could delay product launches or increase compliance costs unexpectedly. A slowdown in life sciences R&D spending by major pharma clients could directly impact future revenue growth trajectories.
What is IRMD's competitive advantage?
IRADiMED possesses a strong intellectual property portfolio that differentiates its diagnostic algorithms in the crowded medical device market. The company benefits from high switching costs for healthcare providers who integrate its software deeply into their existing clinical workflows. Its focus on niche, data-heavy applications creates a defensible moat against larger generalist competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.